[Studies on the effect of a new verucarin E analog WER I on the growth of experimental neoplasms].
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D005260:Female; D008114:Liver Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D051379:Mice; D008815:Mice, Inbred Strains; D051381:Rats; D011919:Rats, Inbred Strains; D012513:Sarcoma, Experimental / Q000188:drug therapy* / Q000473:pathology; D012717:Sesquiterpenes / Q000627:therapeutic use*; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014255:Trichothecenes / Q000627:therapeutic use*
D000903:Antibiotics, Antineoplastic; D012717:Sesquiterpenes; D014255:Trichothecenes; C032865:VER I
Badania wpływu nowego analogu werukaryny E--WER I na wzrost nowotworów doświadczalnych.